Dr. Mark McLaughlin graduated with an MSci (Hons) degree in Chemistry in 2010 from Queen’s University Belfast, and continued in the same institution for his PhD. His PhD, carried out under the supervision of Prof. Matthew Cook focussed on the development of transition metal catalysed hydrometallation reactions and their subsequent use in synthesis. During his PhD, he was awarded a prestigious internship at Genentech, San Francisco, working with Dr James Crawford on the development of irreversible BTK inhibitors. Additionally he was a Syngenta postgraduate scholarship finalist in 2012 and a RSC delegate at J-NOST in Bhopal, India in 2013.
After being awarded his PhD in 2014, he moved to the Institute of Cancer Research, London as a CRUK postdoctoral training fellow under the supervision of Prof. Julian Blagg where he worked on the design and synthesis of selective chemical probes for JMJD2, a lysine demethylase enzyme implicated in various cancers.
In May 2016 he joined the group of Prof. Paul Brennan at the University of Oxford as a postdoctoral fellow focussing his research interests in fragment based approaches to small molecule inhibitors of several important biological targets.
In January 2018 he moved to Manchester Metropolitan University as a lecturer in medicinal chemistry where his research group focussed on the development of novel synthetic methodology.
After three productive and enjoyable years at Manchester Met, the group moved to the Department of Chemistry at Lancaster University, where the group continue to work on catalysis and medicinal chemistry projects.